Evidence map›Paper›PMID 33691747›Full record

ArticleOrphanet journal of rare diseases2021

Homocystinuria patient and caregiver survey: experiences of diagnosis and patient satisfaction.

T Morrison, F Bösch, M A Landolt, V Kožich, M Huemer, A A M Morris

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Characterization of Treatment Utilization in a Metabolic Genetics Clinic.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

T MorrisonHCU Network Australia, Baulkham Hills, Australia.
F BöschDivision of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
M A LandoltDivision of Child and Adolescent Health Psychology, Department of Psychology, University of Zurich, Zurich, Switzerland.
V KožichDepartment of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine, General University Hospital, Prague, Czech Republic.
M Huemer *Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. martina.huemer@kispi.uzh.ch.ORCID 0000-0002-0590-678X
A A M Morris *Division of Evolution and Genomic Sciences, Institute of Human Development, University of Manchester, Manchester, UK.
University of Zurich · CHCharles University · CZLandeskrankenhaus Feldkirch · ATManchester Academic Health Science Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe main genetic causes of homocystinuria are cystathionine beta-synthase (CBS) deficiency and the remethylation defects. Many patients present in childhood but milder forms may present later in life. Some countries have newborn screening programs for the homocystinurias but these do not detect all patients.

resultsHCU Network Australia is one of the very few support groups for patients with homocystinurias. Here we report the results of its survey of 143 patients and caregivers from 22 countries, evaluating current diagnostic pathways and management for the homocystinurias. Most (110) of the responses related to patients with CBS deficiency. The diagnosis was made by newborn screening in 20% of patients and in 50% of the others within 1 year of the initial symptom but in 12.5% it took over 15 years. The delay was attributed mainly to ignorance of the disease. Physicians need to learn to measure homocysteine concentrations in children with neurodevelopmental problems, and in patients with heterogeneous symptoms such as thromboembolism, dislocation of the optic lens, haemolytic uraemic syndrome, and psychiatric disease. Even when the diagnosis is made, the way it is communicated is sometimes poor. Early-onset CBS deficiency usually requires a low-protein diet with amino acid supplements. More than a third of the participants reported problems with the availability or cost of treatment. Only half of the patients always took their amino acid mixture. In contrast, good adherence to the protein restriction was reported in 98% but 80% said it was hard, time-consuming and caused unhappiness.

conclusionsThere is often a long delay in diagnosing the homocystinurias unless this is achieved by newborn screening; this survey also highlights problems with the availability and cost of treatment and the palatability of protein substitutes.

Indexed as

HomocystinuriaAustraliaCaregiversChildCystathionine beta-SynthaseHumansInfant, NewbornPatient SatisfactionCystathionine beta-SynthaseCystathionine beta-synthase deficiencyDelay in diagnosisPatient reported outcomePatient support groupsRemethylation disorders

Identifiers

PMID33691747
PMCPMC7945666
OpenAlexW3134520279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.